Panelists discuss advances in targeted therapy for small cell lung cancer (SCLC), focusing on the impact of recently approved therapies on survival benefits, the mechanisms of DLL3-directed bispecifics, and the integration of these therapies into updated NCCN guidelines for extensive stage SCLC.
EP. 1: Clinical Impressions and Therapy Goals
September 30th 2024Panelists discuss how managing extensive stage small cell lung cancer involves balancing the survival benefits of subsequent therapies with the risks of treatment-related adverse events, emphasizing the importance of individualized treatment strategies.
Watch
EP. 2: Considerations for Extended Chemoimmunotherapy
September 30th 2024Dr. Sabari discusses how, for extensive stage small cell lung cancer (ES-SCLC) that progresses within six months after platinum-based chemoimmunotherapy and immunotherapy maintenance, options like lurbinectedin, topotecan, and irinotecan are considered viable subsequent treatments due to their proven effectiveness in similar clinical scenarios.
Watch